Sorrento Therapeutics, Inc. (SRNE)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2022 | 472.84 Million USD | -31.95% |
| 2021 | 694.81 Million USD | 29.67% |
| 2020 | 535.82 Million USD | -3.91% |
| 2019 | 557.63 Million USD | -17.35% |
| 2018 | 674.72 Million USD | 40.63% |
| 2017 | 479.77 Million USD | 19.47% |
| 2016 | 401.58 Million USD | 16.9% |
| 2015 | 343.51 Million USD | 142.7% |
| 2014 | 141.54 Million USD | 52.88% |
| 2013 | 92.58 Million USD | 1265.19% |
| 2012 | 6.78 Million USD | 48.43% |
| 2011 | 4.56 Million USD | -19.67% |
| 2010 | 5.68 Million USD | 60.05% |
| 2009 | 3.55 Million USD | 800.78% |
| 2008 | 394.52 Thousand USD | 1703.21% |
| 2007 | 21.87 Thousand USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q1 | 460.06 Million USD | -2.7% |
| 2023 Q2 | 456.69 Million USD | -0.73% |
| 2022 Q4 | 472.84 Million USD | -23.19% |
| 2022 Q1 | 855.63 Million USD | 10.7% |
| 2022 FY | 472.84 Million USD | -31.95% |
| 2022 Q3 | 615.61 Million USD | -2.61% |
| 2022 Q2 | 632.13 Million USD | -26.12% |
| 2021 Q4 | 772.89 Million USD | 2.67% |
| 2021 Q1 | 613.61 Million USD | 14.52% |
| 2021 Q2 | 778.92 Million USD | 26.94% |
| 2021 Q3 | 752.79 Million USD | -3.36% |
| 2021 FY | 694.81 Million USD | 29.67% |
| 2020 Q4 | 535.82 Million USD | -11.01% |
| 2020 Q3 | 602.08 Million USD | 12.95% |
| 2020 Q2 | 533.06 Million USD | -0.65% |
| 2020 Q1 | 536.55 Million USD | -3.78% |
| 2020 FY | 535.82 Million USD | -3.91% |
| 2019 FY | 557.63 Million USD | -17.35% |
| 2019 Q2 | 587.04 Million USD | -3.68% |
| 2019 Q4 | 557.63 Million USD | -0.58% |
| 2019 Q1 | 609.47 Million USD | -2.34% |
| 2019 Q3 | 560.87 Million USD | -4.46% |
| 2018 Q2 | 452.52 Million USD | 3.58% |
| 2018 Q4 | 624.08 Million USD | 6.14% |
| 2018 FY | 674.72 Million USD | 40.63% |
| 2018 Q1 | 436.87 Million USD | 1.22% |
| 2018 Q3 | 587.96 Million USD | 29.93% |
| 2017 FY | 479.77 Million USD | 19.47% |
| 2017 Q1 | 345.22 Million USD | -14.03% |
| 2017 Q2 | 384.76 Million USD | 11.45% |
| 2017 Q3 | 484.78 Million USD | 25.99% |
| 2017 Q4 | 431.61 Million USD | -10.97% |
| 2016 FY | 401.58 Million USD | 16.9% |
| 2016 Q1 | 273.77 Million USD | -20.3% |
| 2016 Q2 | 351.4 Million USD | 28.35% |
| 2016 Q3 | 279.05 Million USD | -20.59% |
| 2016 Q4 | 401.58 Million USD | 43.91% |
| 2015 FY | 343.51 Million USD | 142.7% |
| 2015 Q2 | 132.81 Million USD | 1.19% |
| 2015 Q1 | 131.25 Million USD | -7.27% |
| 2015 Q3 | 325.29 Million USD | 144.92% |
| 2015 Q4 | 343.51 Million USD | 5.6% |
| 2014 Q2 | 110.32 Million USD | 21.75% |
| 2014 Q3 | 104.12 Million USD | -5.61% |
| 2014 FY | 141.54 Million USD | 52.88% |
| 2014 Q4 | 141.54 Million USD | 35.93% |
| 2014 Q1 | 90.61 Million USD | -2.12% |
| 2013 Q4 | 92.58 Million USD | 143.75% |
| 2013 FY | 92.58 Million USD | 1265.19% |
| 2013 Q2 | 7.78 Million USD | -36.15% |
| 2013 Q1 | 12.19 Million USD | 79.87% |
| 2013 Q3 | 37.98 Million USD | 387.66% |
| 2012 Q2 | 8.91 Million USD | 139.42% |
| 2012 Q4 | 6.78 Million USD | -14.07% |
| 2012 Q3 | 7.89 Million USD | -11.5% |
| 2012 FY | 6.78 Million USD | 48.43% |
| 2012 Q1 | 3.72 Million USD | -18.48% |
| 2011 Q1 | 5.59 Million USD | -1.68% |
| 2011 Q4 | 4.56 Million USD | 38.01% |
| 2011 Q3 | 3.31 Million USD | -15.03% |
| 2011 Q2 | 3.89 Million USD | -30.33% |
| 2011 FY | 4.56 Million USD | -19.67% |
| 2010 Q3 | 2.16 Million USD | -8.54% |
| 2010 FY | 5.68 Million USD | 60.05% |
| 2010 Q2 | 2.37 Million USD | -16.44% |
| 2010 Q4 | 5.68 Million USD | 162.21% |
| 2010 Q1 | 2.83 Million USD | -20.14% |
| 2009 FY | 3.55 Million USD | 800.78% |
| 2009 Q1 | 371.82 Thousand USD | -5.75% |
| 2009 Q2 | 292.18 Thousand USD | -21.42% |
| 2009 Q3 | 4.05 Million USD | 1287.91% |
| 2009 Q4 | 3.55 Million USD | -12.37% |
| 2008 Q1 | 17.13 Thousand USD | -21.67% |
| 2008 FY | 394.52 Thousand USD | 1703.21% |
| 2008 Q4 | 394.52 Thousand USD | -9.82% |
| 2008 Q3 | 437.49 Thousand USD | 2099.62% |
| 2008 Q2 | -21.87 Thousand USD | -227.66% |
| 2007 Q1 | 85.85 Thousand USD | 0.0% |
| 2007 Q3 | 30.01 Thousand USD | -43.54% |
| 2007 Q4 | 21.87 Thousand USD | -27.1% |
| 2007 Q2 | 53.15 Thousand USD | -38.09% |
| 2007 FY | 21.87 Thousand USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| America Great Health | 299.12 Thousand USD | -157972.27% |
| Ampio Pharmaceuticals, Inc. | 5.73 Million USD | -8143.375% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -3117.693% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -1414.785% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -14584.472% |
| Better Therapeutics, Inc. | 22.94 Million USD | -1960.934% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -1548.905% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -12586.495% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -2201.597% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -2138.508% |
| Evelo Biosciences, Inc. | 64.44 Million USD | -633.756% |
| Evolutionary Genomics, Inc. | 2.35 Million USD | -19989.136% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | -566.0% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -1708.806% |
| Innovation1 Biotech Inc. | 75.99 Thousand USD | -622115.204% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -3785.611% |
| Molecular Templates, Inc. | 35.38 Million USD | -1236.348% |
| Navidea Biopharmaceuticals, Inc. | 4.37 Million USD | -10716.162% |
| NexImmune, Inc. | 8.59 Million USD | -5402.011% |
| Orgenesis Inc. | 14.55 Million USD | -3149.313% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -3906.44% |
| Point of Care Nano-Technology, Inc. | 124.64 Thousand USD | -379255.439% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -8224.054% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -120440.961% |
| Statera Biopharma, Inc. | 21.16 Million USD | -2133.571% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -4579.268% |
| Trevena, Inc. | 40.6 Million USD | -1064.487% |
| Vaxxinity, Inc. | 44.35 Million USD | -966.083% |
| Vaccinex, Inc. | 3.63 Million USD | -12922.308% |
| Vicapsys Life Sciences, Inc. | 39.65 Thousand USD | -1192254.247% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | -734.051% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -84986.78% |